Work at Bristol Myers Squibb Co. has led to the discovery of selective Toll-like receptor 7 (TLR7) agonists with potential as anticancer agents.

Xtalpi Inc. and Parthenon Therapeutics Inc. (now known as Incendia Therapeutics Inc.) have entered into a collaboration to discover novel therapeutic antibodies for the treatment of solid tumors.

Wave Life Sciences Ltd. has submitted its first clinical trial application (CTA) for WVE-006 for α1-antitrypsin deficiency (AATD).

Antoxa Corp. and Swiftpharma BV have signed an exclusive collaboration agreement to support the development and commercialization of a plant-made monoclonal antibody against ricin exposure.

Tetra Pharm Technologies Aps has completed preclinical testing and announced promising in vivo study results with its candidate compound, TPT-0301, which targets the endocannabinoid system.

A large-scale genetic study found 26 risk loci for epilepsy, a chronic brain disease with multiple forms, not all of them heritable. The work, by more than 300 authors from the International League Against Epilepsy (ILAE), investigated seven different subtypes of this neurological condition. “There are over 100 genes that we know can harbor mutations that cause epilepsy,” the co-corresponding author Gianpiero Cavalleri told BioWorld. These genes have rare forms that cause that epilepsy. However, “this particular GWAS is focused more on common forms of epilepsy,” he said.